Company Summary - NextGen Group PLC (LSE:NGG)
0.14p
0.00p
Pharmaceuticals & BiotechnologyMarket cap: £10.146m
NEW Explore our new and improved report for NextGen Group PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Research and development services in the Biomarker arena
| Financials - Interim (9/9/2011) | ||
|---|---|---|
| Turnover | £m | 0.59 |
| Pre-tax Profit | £m | -0.99 |
| EPS | p | -0.00 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Klaus Rosenau | Chairman & Chief Executive |
| Leif Hamo | Finance Director |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
NextGen Sciences Inc; NextGen Sciences Ltd
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Convertible Loan Agreement | 02/02/2012 |
| Holding(s) in Company | 14/12/2011 |
| Holding(s) in Company | 02/12/2011 |
For more information
and investor relations, visit the
NextGen Group PLC company website: